AARD
Aardvark Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$90.10M
P/E Ratio
—
EPS
$-2.93
Beta
—
52W High
$17.94
52W Low
$3.35
50-Day MA
$8.81
200-Day MA
$11.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-62.69M |
| Operating Margin | 0.00% |
| Return on Equity | -64.40% |
| Return on Assets | -40.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.89 |
| Price-to-Book | 0.88 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $21.82M |
| Float | $11.22M |
| % Insiders | 16.15% |
| % Institutions | 59.17% |
Analyst Ratings
Consensus ($16.90 target)
8
Buy4
HoldData last updated: 4/7/2026